• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重指数对第二代药物洗脱支架植入术后长期临床结局的影响:来自国际全球RESOLUTE项目的见解

Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.

作者信息

Diletti Roberto, Garcia-Garcia Hector M, Bourantas Christos, Van Mieghem Nicolas M, van Geuns Robert Jan, Muramatsu Takashi, Zhang Yao-Jun, Mauri Laura, Belardi Jorge, Silber Sigmund, Widimsky Petr, Leon Martin, Windecker Stephan, Meredith Ian, Neumann Franz-Josef, Yeung Alan C, Saito Shigeru, Liu Minglei, van Leeuwen Frank, Serruys Patrick W

机构信息

Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.

出版信息

Catheter Cardiovasc Interv. 2015 May;85(6):952-8. doi: 10.1002/ccd.25828. Epub 2015 Feb 17.

DOI:10.1002/ccd.25828
PMID:25689692
Abstract

BACKGROUND

An increased body mass index (BMI) is associated with a high risk of cardiovascular disease and reduction in life expectancy. However, several studies reported improved clinical outcomes in obese patients treated for cardiovascular diseases. The aim of the present study is to investigate the impact of BMI on long-term clinical outcomes after implantation of zotarolimus eluting stents.

METHODS

Individual patient data were pooled from the RESOLUTE Clinical Program comprising five trials worldwide. The study population was sorted according to BMI tertiles and clinical outcomes were evaluated at 2-year follow-up.

RESULTS

Data from a total of 5,127 patients receiving the R-ZES were included in the present study. BMI tertiles were as follow: I tertile (≤ 25.95 kg/m(2) -Low or normal weight) 1,727 patients; II tertile (>25.95 ≤ 29.74 kg/m(2) -overweight) 1,695 patients, and III tertile (>29.74 kg/m(2) -obese) 1,705 patients. At 2-years follow-up no difference was found for patients with high BMI (III tertile) compared with patients with normal or low BMI (I tertile) in terms of target lesion failure (I-III tertile, HR [95% CI] = 0.89 [0.69, 1.14], P = 0.341; major adverse cardiac events (I-III tertile, HR [95% CI] = 0.90 [0.72, 1.14], P = 0.389; cardiac death (I-III tertile, HR [95% CI] = 1.20 [0.73, 1.99], P = 0.476); myocardial infarction (I-III tertile, HR [95% CI] = 0.86 [0.55, 1.35], P = 0.509; clinically-driven target lesion revascularization (I-III tertile, HR [95% CI] = 0.75 [0.53, 1.08], P = 0.123; definite or probable stent thrombosis (I-III tertile, HR [95% CI] = 0.98 [0.49, 1.99], P = 0.964.

CONCLUSIONS

In the present study, the patients' body mass index was found to have no impact on long-term clinical outcomes after coronary artery interventions.

摘要

背景

体重指数(BMI)升高与心血管疾病高风险及预期寿命缩短相关。然而,多项研究报告称,接受心血管疾病治疗的肥胖患者临床结局有所改善。本研究旨在探讨BMI对佐他莫司洗脱支架植入术后长期临床结局的影响。

方法

从全球五项试验组成的RESOLUTE临床项目中汇总个体患者数据。根据BMI三分位数对研究人群进行分类,并在2年随访时评估临床结局。

结果

本研究纳入了共5127例接受R-ZES的患者的数据。BMI三分位数如下:第一三分位数(≤25.95kg/m² - 低体重或正常体重)1727例患者;第二三分位数(>25.95≤29.74kg/m² - 超重)1695例患者,第三三分位数(>29.74kg/m² - 肥胖)1705例患者。在2年随访时,高BMI患者(第三三分位数)与正常或低BMI患者(第一三分位数)相比,在靶病变失败(第一至第三三分位数,HR[95%CI]=0.89[0.69,1.14],P=0.341)、主要不良心脏事件(第一至第三三分位数,HR[95%CI]=0.90[0.72,1.14],P=0.389)、心源性死亡(第一至第三三分位数,HR[95%CI]=1.20[0.73,1.99],P=0.476)、心肌梗死(第一至第三三分位数,HR[95%CI]=0.86[0.55,1.35],P=0.509)、临床驱动的靶病变血运重建(第一至第三三分位数,HR[95%CI]=0.75[0.53,1.08],P=0.123)、明确或可能的支架血栓形成(第一至第三三分位数,HR[95%CI]=0.98[0.49,1.99],P=0.964)方面未发现差异。

结论

在本研究中,发现患者的体重指数对冠状动脉介入术后的长期临床结局无影响。

相似文献

1
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.体重指数对第二代药物洗脱支架植入术后长期临床结局的影响:来自国际全球RESOLUTE项目的见解
Catheter Cardiovasc Interv. 2015 May;85(6):952-8. doi: 10.1002/ccd.25828. Epub 2015 Feb 17.
2
Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents.糖尿病患者使用早期药物洗脱支架血运重建后的长期临床和血管造影结果。
Am Heart J. 2012 May;163(5):876-886.e2. doi: 10.1016/j.ahj.2012.02.014.
3
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.经皮冠状动脉介入治疗后病变长度和血管大小对临床结局的影响:来自 SPIRIT(依维莫司洗脱冠状动脉支架系统 XIENCE V 的临床评估)和 COMPARE(真实世界中第二代依维莫司洗脱和紫杉醇洗脱支架)随机试验的汇总分析。
JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016.
4
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.SYNTAX 评分对依维莫司和佐他莫司洗脱支架血运重建后 1 年结局的预后价值:RESOLUTE 所有患者试验的一项亚组研究。
JACC Cardiovasc Interv. 2011 Apr;4(4):432-41. doi: 10.1016/j.jcin.2011.01.008.
5
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.药物洗脱支架血运重建患者的性别对临床和血管造影结局的影响。
JACC Cardiovasc Interv. 2012 Mar;5(3):301-10. doi: 10.1016/j.jcin.2011.11.011.
6
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.与紫杉醇洗脱支架相比,在新发冠状动脉病变患者中,使用佐他莫司洗脱支架可改善晚期临床安全性:来自 ENDEAVOR IV (随机比较冠状动脉疾病患者中使用佐他莫司和紫杉醇洗脱支架)试验的 3 年随访结果。
JACC Cardiovasc Interv. 2010 Oct;3(10):1043-50. doi: 10.1016/j.jcin.2010.07.008.
7
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.重叠使用新一代药物洗脱支架对临床和血管造影结果的影响:来自国际 Global RESOLUTE 计划的五项试验的汇总分析。
Heart. 2013 May;99(9):626-33. doi: 10.1136/heartjnl-2012-303368. Epub 2013 Mar 6.
8
Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.雷帕霉素洗脱支架和球囊血管成形术治疗雷帕霉素洗脱支架内再狭窄的安全性和有效性。
Cardiovasc Revasc Med. 2015 Mar;16(2):84-9. doi: 10.1016/j.carrev.2015.01.004. Epub 2015 Jan 29.
9
Gender differences in patients treated with the zotarolimus-eluting stent at a tertiary medical center.在一家三级医疗中心接受佐他莫司洗脱支架治疗的患者中的性别差异。
J Invasive Cardiol. 2012 Jun;24(6):256-60.
10
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.SPIRIT FIRST 试验:依维莫司洗脱 XIENCE V 冠状动脉支架系统治疗初发冠状动脉病变患者的 5 年临床随访。
Catheter Cardiovasc Interv. 2010 Jun 1;75(7):997-1003. doi: 10.1002/ccd.22428.

引用本文的文献

1
Obesity Paradox: Fact or Fiction?肥胖悖论:事实还是虚构?
Curr Obes Rep. 2023 Jun;12(2):75-85. doi: 10.1007/s13679-023-00497-1. Epub 2023 Feb 20.
2
Impact of body mass index on acute outcome in percutaneous coronary intervention of chronic total occlusion.体重指数对慢性完全闭塞病变经皮冠状动脉介入治疗急性结局的影响
J Saudi Heart Assoc. 2019 Oct;31(4):198-203. doi: 10.1016/j.jsha.2019.06.003. Epub 2019 Jun 24.
3
Relationship of body mass index and waist circumference with clinical outcomes following percutaneous coronary intervention.
体重指数和腰围与经皮冠状动脉介入治疗后临床结果的关系。
PLoS One. 2018 Dec 13;13(12):e0208817. doi: 10.1371/journal.pone.0208817. eCollection 2018.